♦ 2009: Receives the 2009 North American Medical Imaging Emerging Company of the Year Award from Frost & Sullivan for its opto-acoustic imaging technology.
♦ 2008: Receives remaining $1 million from the Texas Emerging Technology Fund (TETF). Award is one of the largest investments the State of Texas had made to date to a private company.
♦ 2008: Receives the prestigious Super Star Award from the San Antonio Technology Accelerator Initiative (SATAI) in recognition for their entrepreneurial development of cutting edge technology in the region.
♦ 2008: Forms a research partnership with the University of Prince Edward Island and Ryerson University of Toronto to develop new biomedical applications for Seno’s opto-acoustic imaging technology.
♦ 2008: Signs licensing agreement with VisualSonics, a world-leader in preclinical high-frequency ultrasound, for the exclusive rights to Seno’s Opto-Acoustic small animal imaging (preclinical) technology.
♦ 2007: Announces completion of its Series A Preferred Stock offering, receiving aggregate proceeds in the amount of $6 million from the offering.
♦ 2007: Announces its participation in the In3 Medical Device Summit. Attendees include some of the biggest dealmakers in the medical device industry, including members of the healthcare investment community.
♦ 2007: Receives $2 million award from the Texas Emerging Technology Fund (TETF). Funding allows the company to further develop its life saving technology for cancer imaging and detection and moves it closer to the global marketplace.
♦ 2007: Introduces new platform technology using opto-acoustics for small animal functional imagingat the Joint Molecular Imaging Conference in Providence, Rhode Island.
♦ 2007: The Joint Molecular Imaging Conference unites medical professionals and scientists with state of the art technology. Scientists and researchers from around the world will have the opportunity to learn about the Imagio® research device that uses Seno’s patented laser opto-acoustic imaging technology.
♦ 2006: Receives more than $3 million to launch commercial operations. Funding will allow the company to further develop patented laser opto-acoustic breast imaging technology for commercial use by doctors and hospitals around the world.
♦ 2005: Seno Medical Instruments, Inc. was founded in September 2005.  The company purchased opto-acoustic prototypes and proprietary test equipment, the core patent, and other associated intellectual properties from Dr. Alexander Oraevsky and Fairway Medical Technologies in exchange for stock.  Dr. Oraevsky, the father of medical opto-acoustics, had validated the science through grants from such nationally recognized institutions as the National Institutes of Health (NIH), the National Cancer Institute (NCI) and the Department of Defense (DOD),  and he continues to provide advice and support to Seno for future applications of this technology.